Co-expression of the Toleragenic Glycoprotein, CD200, with Markers for Cancer Stem Cells

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2007 Oct 30

PMID 17964286

Citations 52

Authors

Brian T Kawasaki

Tashan Mistree

Elaine M Hurt

Madhuri Kalathur

William L Farrar

Affiliations

Soon will be listed here.

Abstract

Tumor immunology fundamentals suggest immunological surveillance has the ability to recognize malignant cells and kill them before a tumor develops. However, cancer cells employ evasion mechanisms whereby the immune system may be actively suppressed or even tolerized to the tumor. Recently cancer stem cells were linked to tumor initiation and formation. However, no reports have addressed whether these cells participate in a tumor's ability to evade immune surveillance. Recently the glycoprotein CD200, expressed within the innate immune system and other tissues and cells, was shown to be involved in tolerance. Here we describe CD200 co-expression with stem cell markers found on prostate, breast, brain, and colon cancers. This is the first report describing an immunomodulatory molecule on epithelial cancer stem cells. This important finding suggests a mechanism by which a tumor might evades immune system detection.

Citing Articles

Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.

Baek S, Cui K Int J Mol Sci. 2025; 26(1.

PMID: 39795972 PMC: 11719565. DOI: 10.3390/ijms26010115.

Stemness in solid malignancies: coping with immune attack.

Agudo J, Miao Y Nat Rev Cancer. 2024; 25(1):27-40.

PMID: 39455862 DOI: 10.1038/s41568-024-00760-0.

Lectins as a promising therapeutic agent for breast cancer: A review.

Singh K, Agrawal L, Gupta R, Singh D, Kathpalia M, Kaur N Breast Dis. 2024; 43(1):193-211.

PMID: 38905027 PMC: 11307042. DOI: 10.3233/BD-230047.

Identification of New Markers of Angiogenic Sprouting Using Transcriptomics: New Role for RND3.

Abbey C, Duran C, Chen Z, Chen Y, Roy S, Coffell A Arterioscler Thromb Vasc Biol. 2024; 44(5):e145-e167.

PMID: 38482696 PMC: 11043006. DOI: 10.1161/ATVBAHA.123.320599.

The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders.

Al-Zubaidi H, Hughes S Br J Biomed Sci. 2023; 80:11573.

PMID: 37822353 PMC: 10563807. DOI: 10.3389/bjbs.2023.11573.

References

Ohyama M, Terunuma A, Tock C, Radonovich M, Pise-Masison C, Hopping S . Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest. 2006; 116(1):249-60. PMC: 1323261. DOI: 10.1172/JCI26043. View

Rosenblum M, Olasz E, Yancey K, Woodliff J, Lazarova Z, Gerber K . Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance?. J Invest Dermatol. 2004; 123(5):880-7. DOI: 10.1111/j.0022-202X.2004.23461.x. View

Hoek R, Ruuls S, Murphy C, Wright G, Goddard R, Zurawski S . Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000; 290(5497):1768-71. DOI: 10.1126/science.290.5497.1768. View

Dean M, Fojo T, Bates S . Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-84. DOI: 10.1038/nrc1590. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J . Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-8. View

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

Collins A, Berry P, Hyde C, Stower M, Maitland N . Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-51. DOI: 10.1158/0008-5472.CAN-05-2018. View

10.

Hurt E, Thomas S, Peng B, Farrar W . Integrated molecular profiling of SOD2 expression in multiple myeloma. Blood. 2006; 109(9):3953-62. PMC: 1874573. DOI: 10.1182/blood-2006-07-035162. View

11.

Inman B, Frigola X, Dong H, Kwon E . Costimulation, coinhibition and cancer. Curr Cancer Drug Targets. 2007; 7(1):15-30. DOI: 10.2174/156800907780006878. View

12.

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Minden M . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8. DOI: 10.1038/367645a0. View

13.

Sharma M, Koltowski L, Ownbey R, Tuszynski G, Sharma M . Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006; 81(2):146-56. DOI: 10.1016/j.yexmp.2006.03.003. View

14.

Lee H, Pienta K, Kim W, Cooper C . The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int J Oncol. 2003; 22(4):921-6. View

15.

OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

16.

Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S . Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006; 25(12):1696-708. DOI: 10.1038/sj.onc.1209327. View

17.

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

18.

Li M, Hsu T, Chen T, Chang S, Lee J, Chen C . The 3C protease activity of enterovirus 71 induces human neural cell apoptosis. Virology. 2002; 293(2):386-95. DOI: 10.1006/viro.2001.1310. View

19.

Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4):263-74. DOI: 10.1038/nrc1586. View

20.

Nathan C, Muller W . Putting the brakes on innate immunity: a regulatory role for CD200?. Nat Immunol. 2001; 2(1):17-9. DOI: 10.1038/83124. View